en · de · es · fr · pt
hplc-notes.peptides4800.com › Faq › Ipamorelin Background And Receptor Selectivity — Worked Examples

Ipamorelin Background And Receptor Selectivity — Worked Examples

By Editorial Desk · published 2025-09-20 · last reviewed 2025-11-08 · Faq

Everything below concerns lyophilization. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2025-11-08. Numbers and descriptions here follow the published literature rather than marketing material.

Ipamorelin Background and Receptor Selectivity

Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.

At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.

Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.

Receptor Mechanism and Secretagogue Action

Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.

At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.

One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.

Ipamorelin at a glance

PropertyValueNotes
Molecular formulaC38H49N9O5Pentapeptide with amidated C-terminus
Molecular weight711.85 g/molMonoisotopic mass
Primary receptorGHS-R1aGhrelin receptor, Gq/11 coupled
Peptide classSynthetic pentapeptideContains two non-natural residues
Reported selectivityLower cortisol and prolactin effectObserved in animal and early human work

Analytical Methods and Storage Stability

Identity and purity assessment of ipamorelin relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength where the peptide backbone absorbs. Mass confirmation is typically obtained by electrospray ionization mass spectrometry or by liquid chromatography coupled to mass spectrometry, comparing the observed mass with the calculated value. Amino acid analysis and peptide mapping after enzymatic digestion can confirm the sequence. Impurity profiles include deletion peptides, truncated fragments, and oxidation products, reported as relative area percentages.

Lyophilized ipamorelin is generally held at minus twenty degrees Celsius or colder, protected from light and moisture. In solution the peptide is less stable, and degradation proceeds through hydrolysis of the amide backbone, oxidation of the histidine residue, and aggregation. Repeated freeze-thaw cycles accelerate these processes, so dividing material into single-use aliquots before freezing is common practice in research settings. Buffered formulations near neutral pH tend to show the slowest degradation, while strongly acidic or basic conditions raise hydrolysis rates. Stability data specific to ipamorelin are sparse, and much guidance is extrapolated from other short peptides.

Related pages on this site

Storage Stability and Analytical Verification

Peptides such as ipamorelin are subject to chemical and physical degradation. Hydrolysis of peptide bonds, oxidation of susceptible residues, and aggregation are common pathways that reduce purity over time. The rate of these processes depends on temperature, moisture, pH, and the number of freeze-thaw cycles a sample undergoes. Because the compound is typically handled as a lyophilized powder, controlling moisture during storage is a central concern. Degradation products can be detected with separation techniques that resolve the parent peptide from related impurities.

Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.

Further detail

Duchenne muscular dystrophy is extremely rare in females (about 1 in 50,000,000 female births). It can occur in females with an affected father and a carrier mother, in those who are missing an X chromosome, or in those who have an inactivated X chromosome (the most common of the rare reasons). The vast majority of clinical trials excluded female patients from enrollment, thus reducing the generalizability of the findings and limiting our understanding of potential sex-specific differences in disease manifestation and treatment response. The daughter of a carrier mother and an affected father will be affected or a carrier with equal probability, as she will always inherit the affected X-chromosome from her father and has a 50% chance of also inheriting the affected X-chromosome from her mother. Disruption of the blood–brain barrier has been seen to be a noted feature in the development of Duchenne muscular dystrophy.

1993/267) Local Government Act 1988 (Defined Activities) (Specified Period) (Woking Borough Council) Regulations 1993 (S.I. 1993/268) Education (Further Education Corporations) Order 1993 (S.I. 1993/269) Education (St Austell Sixth Form College and Mid-Cornwall College) (Dissolution) Order 1993 (S.I. 1993/270) St Austell College (Government) Regulations 1993 (S.I. 1993/271) Hereford and Worcester and Warwickshire (County Boundaries) Order 1993 (S.I. 1993/272) Housing and Planning Act 1986 (Commencement No. 18 and Transitional Provisions) (Scotland) Order 1993 (S.I. 1993/273) Environmental Protection Act 1990 (Commencement No. 13) Order 1993 (S.I. 1993/274) Planning and Compensation Act 1991 (Commencement No. 15) (Scotland) Order 1993 (S.I. 1993/275) River Tay Catchment Area Protection (Renewal) Order 1993 (S.I. 1993/276) Council Tax (Transitional Reduction Scheme) (Scotland) Regulations 1993 (S.I. 1993/277) Removal and Disposal of Vehicles (Amendment) Regulations 1993 (S.I. 1993/278) Guaranteed Minimum Pensions Increase Order 1993 (S.I. 1993/279) Social Security (Contributions) (Re-rating) Order 1993 (S.I. 1993/280) Social Security (Contributions) Amendment (No. 2) Regulations 1993 (S.I. 1993/281) Social Security (Contributions) Amendment (No. 3) Regulations 1993 (S.I. 1993/282) A63 Trunk Road (Selby Bypass) Order 1993 (S.I. 1993/286) A1041 Trunk Road (The Crescent to Brayton Lane) (De-trunking) Order 1993 (S.I. 1993/287) A63 Trunk Road (Whinny Hagg Lane to Magazine Road) (De-trunking) Order 1993 (S.I.

Age-Related Changes in Expression and Activity of Human Hepatic Mitochondrial Glutathione Transferase Zeta1. Zhong G, James MO, Smeltz MG, Jahn SC, Langaee T, Simpson P, Stacpoole PW. Drug Metab Dispos. 2018 Aug;46(8):1118-1128. doi: 10.1124/dmd.118.081810. Epub 2018 May 31. PMID: 29853471 Free PMC article. Glutathione transferase zeta1 (GSTZ1) catalyzes glutathione (GSH)-dependent dechlorination of dichloroacetate (DCA), an investigational drug with therapeutic potential in metabolic disorders and cancer. ...In samples from livers with the GSTZ1C variant, apparent enzyme kin … Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors. Dunbar EM, Coats BS, Shroads AL, Langaee T, Lew A, Forder JR, Shuster JJ, Wagner DA, Stacpoole PW. Invest New Drugs. 2014 Jun;32(3):452-64. doi: 10.1007/s10637-013-0047-4. Epub 2013 Dec 3. PMID: 24297161 Free PMC article. Clinical Trial. All subjects completing at least 1 four week cycle remained clinically stable during this time and remained on DCA for an average of 75.5 days (range 26-312). CONCLUSIONS: Chronic, oral DCA is feasible and well-tolerated in patients with recurrent malignant gliomas …

Sources: en.wikipedia.org

Supporting material

1. "Unichem, Optimus enter into strategic tie-up”. The Hindu Business Line.com. Published on 5 November 2018. 2. “Unichem to acquire 20% stake in Optimus group for Rs 120 cr”. Business-standard.com. Published on 5 November 2018. 3. “Unichem Labs gets USFDA nod for asthma drug”. Economictimes.com. Published on 4-July-2018. 4. “Unichem Labs' Ghaziabad unit gets EIR from USFDA” Thebusinessline.com. Published on 5 June 2018. 2018. 5. “Unichem Laboratories Gets ANDA Approval from U.S. FDA for Valsartan Tablets, USP.” Reuters.com. Published on 7 May 2018. 6. “How Torrent Pharma is integrating Unichem to boost its domestic business.” Business-standard.com. Published on 13 February 2018. 7. “Torrent Pharma completes acquisition of Unichem Laboratories Ltd.” Economictimes.com. Published on 14 December 2017. 8. “This conventional businessman is set for second innings”. Economictimes.indiatimes.com. Published on 4 November 2017. 9. “Unichem Labs gets EIR from USFDA for Goa facility” Economics times.com. Published on 30 June 2017. 10. "Unichem Lab appoints Mr. Bhagwat S. Dhingra as Chief Executive-Domestic Pharma". Moneycontrol.com. 13 August 2012. 11. "Contact Pharmaceutical Company India - Unichem Laboratories". Unichemlabs.com. Retrieved 3 October 2010. 12. "Interview of Dr P A Mody, CEO, Unichem Laboratories Ltd". Indiainfoline.com. Retrieved 3 October 2010. 13. "BSE Plus". Bseindia.com. Retrieved 3 October 2010. 14. "Pharmaceutical Business, Pharma Business Development - Unichem Laboratories". Unichemlabs.com. Retrieved 3 October 2010. 15.

==== Protein-energy malnutrition ==== 'Undernutrition' sometimes refers specifically to protein–energy malnutrition (PEM). This condition involves both micronutrient deficiencies and an imbalance of protein intake and energy expenditure. It differs from calorie restriction in that calorie restriction may not result in negative health effects. Hypoalimentation (underfeeding) is one cause of undernutrition. Two forms of PEM are kwashiorkor and marasmus; both commonly coexist.

The unencapsulated strains are almost always less invasive; however, they can produce an inflammatory response in humans, which can lead to many symptoms. Vaccination with Hib conjugate vaccine is effective in preventing Hib infection but does not prevent infection with NTHi strains. H. influenzae can cause respiratory tract infections including pneumonia, otitis media, epiglottitis (swelling in the throat), eye infections and bloodstream infection, meningitis. It can also cause cellulitis (skin infection), infectious arthritis (inflammation of the joint), and non-gonococcal urethritis (NGU).

Sources: en.wikipedia.org

Supporting material

Described retrospectively as an "outlier", the album had been made by a group in disagreement over method and taste. The more rhythm-and-blues-oriented Haskell and McCulloch both found the music difficult to relate to, and tedious and confusing to record. Collins disliked how his parts were composed, while both Fripp and Haskell detested Sinfield's lyrics. This line-up of the band did not survive much longer than the Lizard recording sessions. Haskell quit the band acrimoniously during initial tour rehearsals, after refusing to sing live with distortion and electronic effects on his voice, and McCulloch departed soon after. With Sinfield not being a musician and Fripp having seemingly given up on the band, Collins was left to search for new members.

Russia has a long, rich tea history dating to 1638 when tea was introduced to Tsar Michael. Social gatherings were considered incomplete without tea, which was traditionally brewed in a samovar. In Pakistan, both black and green teas are used, known locally as sabz chai and kahwah, respectively. Green tea is often served after every meal in the Pashtun belt of Balochistan and in Khyber Pakhtunkhwa. In central and southern Punjab and the metropolitan Sindh region of Pakistan, tea with milk and sugar (sometimes with pistachios, cardamom, etc.), commonly referred to as chai, is widely consumed. It is the most common beverage of households in the region. In the northern Pakistani regions of Chitral and Gilgit-Baltistan, a salty, buttered Tibetan-style tea is consumed. Indian tea culture demonstrates that tea is the most consumed hot beverage in the country. It is common in most homes, offered to guests, consumed in high amounts in domestic and official surroundings, and is made with the addition of milk with or without spices, and usually sweetened. It is sometimes served with biscuits to be dipped in the tea and eaten before consuming the tea. More often than not, it is drunk in "doses" of small cups (referred to as "cutting" chai if sold at street tea vendors) rather than one large cup.

Synthetic molecular motors are molecular machines capable of continuous directional rotation under an energy input. Although the term "molecular motor" has traditionally referred to a naturally occurring protein that induces motion (via protein dynamics), some groups also use the term when referring to non-biological, non-peptide synthetic motors. Many chemists are pursuing the synthesis of such molecular motors. The basic requirements for a synthetic motor are repetitive 360° motion, the consumption of energy and unidirectional rotation. The first two efforts in this direction, the chemically driven motor by Dr. T. Ross Kelly of Boston College with co-workers and the light-driven motor by Ben Feringa and co-workers, were published in 1999 in the same issue of Nature. As of 2020, the smallest atomically precise molecular machine has a rotor that consists of four atoms.

Sources: en.wikipedia.org

Frequently asked questions

What class of compound is ipamorelin?

It is a synthetic pentapeptide belonging to the growth hormone secretagogue family. Its principal characterized target is the ghrelin receptor, also called GHS-R1a. The molecule contains non-natural amino acids and an amidated C-terminus.

How does ipamorelin differ from ghrelin?

Both act at the same G protein-coupled receptor, but ipamorelin is a short synthetic peptide with modified residues rather than the natural 28-amino-acid hormone. Reports describe weaker effects on appetite and on cortisol or prolactin release than those seen with ghrelin. Its resistance to enzymatic breakdown also differs from that of the natural ligand.

Is the mechanism of action fully established?

Receptor binding and downstream calcium signaling are well characterized in cell-based systems. Effects measured in whole organisms are less consistent across studies and species. The extent to which selective receptor behavior drives the observed hormonal profile is still debated.

What receptor does ipamorelin act on?

It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.

Network